HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR Defends Preservative Stance As NGO Says Restrictions On MI, MCI/MI Are ‘Not Working’

Executive Summary

Asked to reconsider its assessments of methylisothiazolinone and the methylchloroisothiazolinone/MI combination, CIR takes a stand against further depletion of the cosmetic industry’s preservative palette in favor of risk-mitigating tools and strategies employed by product formulators. A preview of the CIR Expert Panel's 6-7 December meeting.

You may also be interested in...



Cosmetics Industry In Perplexing Spot: A Trusted Voice, But What Exactly Is The Conversation?

The year 2022 could be a ripe opportunity for industry to inform public opinion amid sweeping policy changes that stand to transform the global cosmetics sector. Consumers may be inclined to listen when business speaks, but that doesn’t mean they’ll like the conversation.

CIR Expert Panel Debates Barley Data Needs, Casts Preservative Pressures As Global Equity Issue

Barley's safe use in food should not be assurance in itself that all barley-derived ingredients under CIR Expert Panel review are without sensitization risks, some panel members contended at the group's 6-7 December meeting. The panel denied an NGO request to reconsider the safety of preservatives MI and MCI/MI in light of new data suggesting increased allergy in the US. Full meeting results.

US FDA’s Sunscreen Proposal Rattles International Trade, And What About Public Health?

European and Japanese trade groups are concerned that the US FDA could be orchestrating global trade disruptions, and possible health crises, with its proposed order to amend the OTC sunscreen monograph in a way that would stymie use of commonly used UV filters with demonstrably safe market histories.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel